Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 8, 2025, reports on the results of a Special Meeting of stockholders held by Jaguar Health, Inc. The filing details the approval of three specific proposals related to capital structure and Nasdaq listing compliance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance metrics.
Material Changes and Voting Results
Three proposals were submitted to and approved by stockholders. The voting record date was October 31, 2025. The following shares were represented at the meeting:
- Common Stock: 747,205 shares voted out of 3,735,835 entitled to vote.
- Series L Preferred Stock: 121.3822 shares (all outstanding) voted.
- Series M Preferred Stock: 235 shares voted out of 260 entitled to vote.
- Series N Preferred Stock: 810.8 shares voted out of 950.8 entitled to vote.
Proposal 1: Approval of Common Stock issuance upon exchange/redemption of Series N Preferred Stock (Nasdaq Rule 5635(d)).
- For: 1,032,716
- Against: 73,065
- Abstained: 14,633
Proposal 2: Approval of issuance of "New PIPE Securities" (Common Stock and Pre-Funded Warrants) pursuant to a September 28, 2025 agreement (Nasdaq Rule 5635(d)).
- For: 2,049,724
- Against: 71,765
- Abstained: 12,805
Proposal 3: Approval of adjournments to solicit additional proxies if necessary.
- For: 2,058,277
- Against: 61,460
- Abstained: 14,557
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) announcing these results but does not contain forward-looking guidance, management commentary on future operations, or specific risk factors within the text of this 8-K. The primary context is the successful execution of a capital raise mechanism (PIPE) and preferred stock conversion, subject to Nasdaq listing rules.
Key Facts for Investor Verification
- Verify the terms of the September 28, 2025 Securities Purchase Agreement referenced in Proposal 2 to understand the valuation and dilution impact of the New PIPE Securities.
- Review the Definitive Proxy Statement filed on November 10, 2025, for detailed descriptions of the Series N Preferred Stock redemption terms and the specific accredited investors involved.
- Confirm the conversion ratios and voting caps (9.99% for Series L/M, 19.99% for Series N) to assess potential future voting power shifts.
- Check subsequent filings for the actual issuance of shares and the cash proceeds received from the PIPE transaction.